在炎症性肠病中药物标表达的肠内异质性
Katelyn Swanson1, Mamoun Younes2
1Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Annals of clinical and laboratory science
|May 27, 2024
概括
在炎症性肠病 (IBD) 中,治疗目标的异质表达可能解释不完全缓解. 在活检中检测目标表达的测试可以帮助优化IBD治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD) 治疗尽管有新疗法,但其缓解率得到了有限的改善.
- 经过治疗后,同一患者的肠道内的组织学愈合可能不均.
- 这种异质性表明,潜在的原因是治疗结果低于最佳.
研究的目的:
- 调查同一肠道内治疗目标的异质表达是否有助于IBD的治疗反应变化.
- 探索不同肠道部位的目标表达和炎症标志物之间的关系.
主要方法:
- 分析了11名IBD患者 (克罗恩病和性结肠炎) 的活体活检,这些患者在多个部位有活跃的炎症.
- 使用免疫组织化学评估TNFα和-JAK1 (p-JAK1) 的表达水平.
- 在炎症峰值区域的量化埃索诺菲尔.
主要成果:
- 在同一IBD患者的不同肠部位表达TNFα和p-JAK1的可变表达.
- 观察到逆表达模式,例如,在一个部位高的p-JAK1/低的TNFα,在另一个部位低的p-JAK1/高的TNFα.
- 强调针对JAK1或TNFα的单剂疗法可能无法在所有炎症区域实现缓解,因为这种异质性.
结论:
- 肠道内的异质标表达是单药疗法对IBD不完全缓解的合理解释.
- 需要进一步的研究来评估粘膜活检测对目标表达的有用性,以指导IBD治疗选择.
- 个性化医疗方法可能对优化IBD管理至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Inflammatory Bowel Disease I: Ulcerative Colitis
165
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
165
Inflammatory Bowel Disease II: Crohn's Disease
217
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
217
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


